Roche’s High-Dose Ocrevus Trial Misses Target, Reinforcing Standard Dose for MS Treatment” ###

Trial Outcome:
The Phase III MUSETTE trial testing high-dose intravenous Ocrevus failed to demonstrate additional benefits in slowing disability progression in relapsing multiple sclerosis (RMS) compared to the standard 600 mg dose2 4 5.

Efficacy of Standard Dose:
The currently approved 600 mg dose of Ocrevus continues to show low rates of disability progression and boasts the lowest annualized relapse rate (ARR) observed in a Phase III RMS study2 5.

Safety Profile:
Both the high-dose and standard dose were well tolerated, with no new safety concerns reported during the MUSETTE trial4 5.

Market Position:
Ocrevus remains the most prescribed disease-modifying therapy for MS globally, treating over 400,000 patients to date. It has set a new standard of care in MS treatment2 4 8.

Expansion of Options:
Roche recently introduced a subcutaneous formulation of Ocrevus, which offers comparable efficacy to intravenous administration and is designed for increased convenience and accessibility1 4 6.

Future Focus:
Roche is investing in new forms of Ocrevus delivery, such as a high-concentration formulation for on-body devices, while also exploring innovative treatments for neurological disorders beyond MS2 8.